Retatrutide

Triple-action metabolic optimization

$549/mo

Virtual consult + lab work required

This peptide requires a brief virtual visit and recent bloodwork before our team can prescribe.

Details

Virtual Consult

Our licensed provider reviews your health profile via secure video — typically 10 minutes. Required for any peptide prescription.

Required Labs

Comprehensive Metabolic Panel (CMP)
Lipid Panel
HbA1c
Thyroid Panel
Liver Function Tests

Refund Policy: If found not eligible due to health reasons after consultation, you will receive a full refund.

Product Details

About Retatrutide

Mechanism of Action

Retatrutide is a groundbreaking triple-agonist peptide that simultaneously activates three key metabolic hormone receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. This triple mechanism creates a comprehensive metabolic intervention unmatched by single or dual agonist therapies. The GIP and GLP-1 components work to reduce appetite and improve insulin sensitivity, while the glucagon component uniquely increases energy expenditure and promotes fat oxidation, creating a powerful synergy for weight loss.

Scientific Background

The addition of glucagon receptor agonism represents a paradigm shift in obesity pharmacotherapy. While GIP and GLP-1 primarily work through appetite suppression and metabolic regulation, glucagon activation increases hepatic fat oxidation, enhances thermogenesis, and promotes lipolysis. This triple-receptor approach addresses obesity through multiple complementary pathways: appetite regulation, glucose homeostasis, energy expenditure, and direct fat metabolism. Early phase 2 trials suggest this combination may overcome the metabolic adaptation (weight loss plateau) commonly seen with diet or single-mechanism therapies.

Clinical Applications

Currently in advanced clinical development, retatrutide has shown exceptional promise in phase 2 trials, with participants achieving weight loss exceeding 24% at the highest doses studied. The triple mechanism appears particularly beneficial for patients with significant metabolic dysfunction, including those with insulin resistance, fatty liver disease, and metabolic syndrome. While not yet FDA-approved, retatrutide represents the next generation of metabolic therapeutics and may offer superior outcomes for patients who have not achieved adequate results with existing GLP-1 or dual agonist therapies.

Evidence-Based

Clinical Research & Studies

Backed by peer-reviewed research from leading medical journals

2023

Peer Reviewed

Phase 2 trial of retatrutide in obesity: A triple hormone receptor agonist

At 48 weeks, retatrutide produced dose-dependent weight loss ranging from 8.7% (1mg) to 24.2% (12mg), representing the highest weight loss observed in any obesity pharmacotherapy trial to date. Significant improvements in liver fat, lipid profiles, and blood pressure were also noted.

Read Full Study

2023

Peer Reviewed

Triple agonism: The future of metabolic disease treatment

Review examining the mechanisms and clinical potential of triple incretin-glucagon receptor agonism, highlighting synergistic effects on weight loss, glucose control, and cardiovascular health beyond what is achievable with dual agonism.

Read Full Study

Retatrutide

About Retatrutide

How It Works

Mechanism of Action

Scientific Background

Clinical Applications

Key Benefits

Treatment Protocol

Safety & Considerations

Clinical Research & Studies

Phase 2 trial of retatrutide in obesity: A triple hormone receptor agonist

Triple agonism: The future of metabolic disease treatment

Related Resources

Similar Peptide Therapies

Tirzepatide

Semaglutide

Educational Articles

The Future of Weight Loss: Dual and Triple Agonist Peptides

Understanding GLP-1 Agonists: The Science Behind Weight Loss

Retatrutide: The Next Generation of Weight Loss Medicine